For many healthy, non-smoking women without cardiovascular risk factors, combined pills can be continued through the 40s, and guidelines even allow using them as an alternative to menopausal hormone therapy under age 50 for symptom relief and bone protection.

At age 50, though, the guideline default is to switch off combined pills to a non-hormonal method or a progestogen-only option, largely on safety grounds. Safety of combined pills specifically past age 50 has not been studied and is formally named as a research gap, so staying on it past 50 is a judgment call, not a guideline-backed default.

What to know about this answer

This is a genuine, unresolved disagreement among credentialed clinicians, not a fringe debate: one side says the pill is the right symptom-control tool through perimenopause because it reliably overrides erratic ovarian hormone output, the other side says switch to standard hormone therapy as early as contraception allows, because of what is known about clot risk in older pill users.

What the research shows, and which source each finding rests on

Age alone never makes a combined pill unacceptably risky; the eligibility category only moves from 1 to 2 with age, and it takes an added risk factor such as smoking, hypertension, or migraine with aura to raise it further.

A[1]

Combined pills can be used in eligible women under 50 as an alternative to menopausal hormone therapy for relief of menopausal symptoms and prevention of bone density loss.

A[2]

At age 50, the guideline recommendation is to stop combined hormonal contraception and switch to a non-hormonal method or a progestogen-only method.

A[2]

The safety of combined hormonal contraception in women over 50 is explicitly named as a research gap by the guideline body; there is no dedicated safety evidence for continuing past that age.

A[2]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

stay on the pill through perimenopause

guideline bodies and clinicians who favor continuing combined pills

Only a contraceptive-strength hormone dose reliably overrides the erratic, unpredictable hormone swings of a still-functioning ovary and controls heavy bleeding; standard menopausal hormone doses are generally not strong enough to do that.

A[2]E[3]

switch to standard hormone therapy as soon as possible

clinicians who favor an earlier switch

A large case-control study found oral contraceptive users over 50 had over six times the clot risk of non-users, while non-oral (transdermal) hormone therapy carried no increased clot risk at all, which argues for moving off oral contraceptive-strength estrogen once contraception can be handled another way.

C[4]

What would settle it: A randomized trial comparing low-dose combined pills against transdermal estrogen plus a separate contraceptive method in symptomatic women aged 42-50, measuring symptom control, bleeding, and clotting markers. No such trial exists.

What is really going on here

  1. No trial has ever compared combined pills directly against standard menopausal hormone therapy in perimenopausal women for symptom control, bleeding, or quality of life, so this remains a values-and-risk-tolerance decision rather than a guideline-settled one.
  2. The guideline's own permission to use the pill as an alternative to hormone therapy under 50, combined with its mandate to stop at 50, is a compromise position, not a resolution of the underlying debate.

Questions for your doctor

  1. Given my personal risk factors, is it safe for me to continue the pill through my 40s?
  2. At what point would you recommend I switch off the combined pill, and to what?
  3. Would switching to standard hormone therapy control my bleeding as well as the pill does?
  4. What would you watch for that might change this recommendation earlier?

Questions with no answer yet

Is combined pill use actually less safe in women over 50 than continuing it in women in their 40s, or has this simply never been directly studied?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The safety of combined hormonal contraception in women over 50 is explicitly named as a research gap by the guideline body; there is no dedicated safety evidence for continuing past that age, on either side of the argument.

What would test it: Dedicated safety research on combined pill use specifically in women over 50, comparing outcomes against both continued younger use and against switching to standard hormone therapy.

Does standard-dose hormone therapy ever control heavy perimenopausal bleeding as effectively as a contraceptive-strength pill does, or is the pill genuinely doing something a lower dose cannot?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: One clinical argument holds that a contraceptive-strength dose reliably overrides erratic ovarian hormone output and controls heavy bleeding in a way standard menopausal doses cannot; no trial has directly compared the two approaches for bleeding control specifically.

What would test it: A randomized trial comparing low-dose combined pills against transdermal estrogen plus a separate contraceptive method in symptomatic perimenopausal women aged 42-50, powered for bleeding control specifically.

Sources

  1. 1.U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. · Systematic review or guideline
  2. 2.FSRH. Contraception for Women Aged Over 40 Years. Guideline, August 2017 (amended September 2019, further amended July 2023).Systematic review or guideline
  3. 3.Mary Claire Haver, MD. Menopause Q and A (video transcript).Review, opinion or mechanism
  4. 4.The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.Roach REJ, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013;11(1):124-31. · Observational study

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides